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A B S T R A C T
Protein disulfide isomerases (PDI) are a family of redox chaperones that catalyze formation or isomerization of disulfide bonds in proteins. Previous studies have
shown that one member, PDIA3, interacts with influenza A virus (IAV) hemagglutinin (HA), and this interaction is required for efficient oxidative folding of HA in
vitro. However, it is unknown whether these host-viral protein interactions occur during active infection and whether such interactions represent a putative target for
the treatment of influenza infection. Here we show that PDIA3 is specifically upregulated in IAV-infected mouse or human lung epithelial cells and PDIA3 directly
interacts with IAV-HA. Treatment with a PDI inhibitor, LOC14 inhibited PDIA3 activity in lung epithelial cells, decreased intramolecular disulfide bonds and
subsequent oligomerization (maturation) of HA in both H1N1 (A/PR8/34) and H3N2 (X31, A/Aichi/68) infected lung epithelial cells. These reduced disulfide bond
formation significantly decreased viral burden, and also pro-inflammatory responses from lung epithelial cells. Lung epithelial-specific deletion of PDIA3 in mice
resulted in a significant decrease in viral burden and lung inflammatory-immune markers upon IAV infection, as well as significantly improved airway mechanics.
Taken together, these results indicate that PDIA3 is required for effective influenza pathogenesis in vivo, and pharmacological inhibition of PDIs represents a
promising new anti-influenza therapeutic strategy during pandemic and severe influenza seasons.
1. Introduction
Viruses harness their host cell transcriptional machinery and en-
doplasmic reticulum (ER) to express and properly fold and mature virus
proteins, respectively [1]. Viral proteins often rely on the redox-de-
pendent formation of disulfide bonds (-S-S-) for stability and function
[2]. In general disulfide bonds within membrane and secretory proteins
are constructed in the ER and require ER-localized oxidoreductases
[3–5]. One of these oxidoreductases is protein disulfide isomerase (PDI)
A3, which belongs to a family of PDIs that catalyze formation and
isomerization of disulfide bonds within nascent peptides in the ER
[6,7]. PDIA3 is unique among other PDIs in that it has an enhanced
specificity towards glycoproteins owing to its interactions with calre-
ticulin and calnexin, two lectin binding chaperone proteins within the
ER [8]. In addition to numerous roles with in the cell, recent studies
have linked PDIA3 with various cancers and the onset of
neurodegenerative disorders [9,10], though its role during viral infec-
tion is less well studied.
Influenza specifically infects and replicates in lung epithelial cells
due to the presence of compatible sialic acid residues that can bind to
influenza hemagglutinin (HA) [11,12]. Previous work has shown that
influenza HA contains several disulfide bonds and traverses through the
ER to attain its final conformation via ER based folding and glycosy-
lation [13,14]. PDIA3 has been shown to interact with IAV-HA and to
facilitate disulfide bond formation in HA during its passage through the
ER [15]. It is also evident that these disulfide bonds formed by PDIA3
are essential for HA activity in vitro [15–17]. Despite in vitro evidence it
is not well established whether PDIA3 is required for viral burden in
vivo, nor is it known about the effect of PDIA3 deletion has on the
disulfide status and maturation of HA during active IAV infection in
primary lung epithelial cells and in mouse lungs.
In this study, we observed that PDIA3 is specifically upregulated in
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IAV-infected lung epithelial cells and mouse lungs as compared to other
PDI family members. Additionally, the newly discovered small mole-
cule inhibitor of PDI, [18] LOC14 exhibited the capacity to inhibit re-
combinant (r)PDIA3 at an IC50 of approximately 5 µM. Treatment of
IAV-infected primary mouse tracheal epithelial cells (MTECs) with
LOC14 resulted in decreased viral burden and pro-inflammatory cyto-
kine production. IAV-HA showed a deficiency in disulfide bonds in cells
treated with LOC14. Furthermore, this deficiency of disulfide bonds
also decreased mature IAV-HA, indicating that PDI inhibition affects HA
maturation within the host cell. Following influenza infection, mice
with lung epithelium-specific knockout of Pdia3 showed decreased
overall viral burden, reduced inflammation and improved lung me-
chanics.
2. Results
2.1. PDIA3 expression is increased following IAV infection
Wild type (C57BL/6NJ-WT) mice were infected with 2000 egg in-
fectious units (EIU) of influenza A virus (IAV) strain H1N1 (PR8) and
lung lysates were analyzed for PDI expression. Six days post infection a
significant increase in Pdia3 transcripts were observed when compared
to other Pdia gene transcripts (Fig. 1A). Mice infected with replication-
deficient, UV irradiated (mock) virus, did not show any increases in
Pdia3, suggesting the Pdia3 induction depends on active viral replica-
tion. We next examined PDIA3 protein expression in the lung sections
of PR8 infected WT mice, and observed a marked increase in PDIA3
levels predominantly in the bronchial epithelial cells in mice infected
with PR8 compared to mock treated mice (Fig. 1B). Next, we sought to
determine if this increase following IAV infection was exclusive to PR8
H1N1 or also prevalent in other influenza strains. Shoemaker et al. [19]
have performed microarray using lung homogenates of mice infected
with various strains of influenza virus, to examine gene expression over
different time points. A retrospective analysis of this microarray data
set (GSE63786) revealed Pdia3 is the only Pdi significantly upregulated
compared to uninfected controls at 72 h, 120 h, and 168 h post infection
with various strains of IAV (Fig. 1C & S1). A similar microarray ex-
periment was performed by Gerlach et al. [20] in human lung epithelial
cells 36 h post infection and a retrospective analysis of this data set
(GSE48466) also revealed significantly upregulated PDIA3 in response
to pandemic influenza infection (Fig. 1D). Despite increased expression
of PDIA3 in response to seasonal influenza infection, this was not found
to be statistically significant (Fig. 1D).
PDIA3 is known to interact with the hemagglutinin (HA) protein of
IAV to construct disulfide bonds (-S-S-) in HA of IAV [15]. We per-
formed immunoprecipitations (IPs) in human bronchial epithelial
(HBE) cells after IAV infection. Upon analysis of the im-
munoprecipitated samples by western blot, we found both increased
PDIA3 expression, as well as high levels of HA co-immunoprecipitating
with PDIA3 (Fig. 1E). Western blots of whole cell lysate (WCL) showed
trends in increases in HA and PDIA3, and no alterations in GAPDH were
observed (Fig. 1E and Fig S1,B). Next, we knocked down PDIA3 using
siRNA and then lung epithelial cells were infected with IAV or mock
virus. Subsequent Western blot analysis showed that knockdown of
PDIA3 decreased levels of HA in IAV infected cells as compared to
scrambled siRNA transfected cells (Fig. 1F and Fig S1C). These results
suggest following IAV infection PDIA3 is predominantly induced in
human and mouse lung epithelial cells, and siRNA mediated decrease in
PDIA3 expression diminish IAV-HA production in lung epithelial cells.
2.2. PDI inhibitors decrease PDIA3 activity and influenza protein
production
PDIs play important roles in the folding of cellular proteins, and the
prototypical PDI, PDIA1, has been found to be implicated in numerous
diseases [21]. As such there are several commercially available small
molecule inhibitors that target PDIA1, while little is known regarding
the effect of these inhibitors on other PDIs. It is presumed that these
inhibitors will have inhibitory effect on other PDIs owing to the high
conservation of a thioredoxin-like (CXXC) active site and the high de-
gree of homology between protein binding domains of the various PDI
family members [18,22–24]. We therefore tested four PDI inhibitors:
16F16, LOC14, PACMA31, and CCF 642, all extensively characterized
as inhibitors of PDIA1, for their efficacy to inhibit PDIA3. Reduction of
Dieosine-diglutathione (DiE-GSSG) has been used as an assay to de-
termine PDI activity [25,26]. We first determined that DiE-GSSG could
also be used as a substrate for recombinant PDIA3 (rPDIA3) (Fig. 2A).
Using this assay, we found that 16F16 had minimal effect on the ac-
tivity of rPDIA3, while both PACMA31 and CCF 642 showed inhibitory
effects only at high concentrations (≥100 μM) (data not shown).
However, reversible inhibitor LOC14 (Fig. 2B) exhibited inhibition of
rPDIA3 with an inhibitory capacity at 50% (IC50) of 4.97 μM (Fig. 2C
and D).
It has been previously shown that PDIA3 is required for IAV pro-
pagation [17]. We therefore next examined, if pharmacological PDI
inhibition would alter IAV propagation. We treated primary mouse
tracheal epithelial cells (MTECs) with LOC14 or vehicle control (VC)
prior to IAV infection, during infection, and post infection (Fig. 2E), to
avoid excessive load of inhibitors and cytotoxicity at a given time.
Examination of the cells 24 h post infection via flow cytometry for the
presence of influenza nucleoprotein (NP) [27] (Fig. 2F), detected no NP
in the mock virus infected VC or 300 µM LOC14 treated cells. IAV in-
fected VC group showed an increase in NP and we observed a dose
dependent decrease in the NP+ cells following LOC14 treatment
(Fig. 2F). Using these data we were able to calculate an effective con-
centration 50% (EC50) of 9.952 μM for LOC14 based on the percentage
of NP+ cells (Fig. 2G).
To determine if LOC14 treatment altered PDI activity within the cell
we monitored the reduction of DiE-GSSG by lysates from IAV-infected
cells treated with either LOC14 or vehicle control. We found LOC14
treatment (Fig. 2E), with repeated doses of 10 μM (total 30 μM), de-
creased PDI activity in infected MTECs compared to controls (Fig. 2H).
DiE-GSSG is reported to be a substrate for PDIs [26]. Taken together
these results indicate that LOC14 inhibits the oxidoreductase activity of
PDIA3 and LOC14 can be used to block viral replication.
2.3. LOC14 treatment in primary mouse tracheal epithelial cells (MTECs)
alters disulfide (-S-S-) bonds of HA
Influenza-HA is synthesized as a 70 kDa (HA0) precursor that is
cleaved in the Golgi to yield two fragments of approximately 50 kDa
(HA1) and 20 kDa (HA2) following oligomerization [28]. To determine
if LOC14 alters -S-S- of HA, we treated primary MTECs with LOC14
(Fig. 3A). Briefly, MTECs were treated with 10 μM LOC14 prior to IAV
infection, during infection, and post IAV infection; resulting in a total of
30 μM LOC14. Western blot (WB) analysis showed that LOC14 treat-
ment cause no alterations in HA0 levels compared to vehicle treated
cells in IAV-infected MTECs (Fig. 3B, WCL). However, levels of cleaved
HA1 showed a significant decrease following LOC14 treatment (Fig. 3B,
WCL-WB, Fig S2A). PDIA3 is unique compared to other PDIs in that it
predominantly facilitates -S-S- bonds in glycoproteins that are being
processed and traversing through the ER [29]. Therefore, we next de-
termined whether inhibition of PDIA3 would alter -S-S- bonds of HA.
We used a biotin switch assay to assess disulfides by blocking free cy-
steine sulfhydryl (-SH) groups using N-ethyl maleimide (NEM) and re-
ducing -S-S- bonds with DTT, and then newly revealed -SH groups are
labeled with biotin-conjugated alkylating agent (MPB) (Fig. 3C). This
technique reveals high labeling of proteins with -S-S- bonds and low
labeling of proteins with -SH groups. Subsequent neutravidin pull-down
and Western blot analysis showed drastic decrease in -S-S- bond for-
mation in IAV-HA following LOC14 treatment compared to vehicle
control treated cells infected with IAV (Fig. 3D). We then examined
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Fig. 1. PDIA3 expression is increased following IAV infection. A. Mice were infected intranasally with 2000 EIU of IAV or mock virus. Pdia mRNA levels were
measured in whole lung lysates 6 days post infection (n=4–5 mice/group). B. Confocal immunofluorescence microscopy of mouse lung tissue sections 6 days post
infection with either IAV or mock virus stained with anti-PDIA3 antibody followed by secondary antibody conjugated to Alexa 647. Nuclei were stained with DAPI. C.
Retrospective analysis of microarray data of Pdia1, 3, and 4 mRNA transcript levels (GEO data set GSE63786) Data expressed as Log2 normalized counts. D.
Retrospective analysis of microarray data of PDIA3 mRNA transcript levels from (GEO data set GSE48466). Data expressed as Log2 normalized counts, Data are
expressed as means (± SEM) * p < 0.05, ** p < 0.01, *** p < 0.001, *** * p < 0.001 by ANOVA. E. Western blot analysis of IAV HA: PDIA3 interaction in HBE
cells following PDIA3 immunoprecipitation. Numbers below indicate average densitometry per group of WCL PDIA3 normalized to GAPDH F. Western blot analysis
of IAV HA and PDIA3 in mouse lung epithelial cells transfected with scrambled (-) or Pdia3-specific siRNA (+). Numbers below indicate densitometry of IAV HA
normalized to β actin.
Fig. 2. PDI inhibitor LOC14 inhibits PDIA3 and decreases influenza protein production. A. Kinetics of PDIA3 catalyzed reduction of DiE-GSSG in the presence of
increasing concentrations of recombinant PDIA3. B. Chemical structure of reversible PDI inhibitor LOC14. C. Dose dependent inhibition of PDIA3 reductase activity
with LOC14. Heat-treated rPDIA3, alkylated (NEM) rPDIA3, and LOC14 without PDIA3 were included as controls. D. IC50 of LOC14 for PDIA3 determined based on
the initial rate of fluorescence formation from C. E. Treatment regimen for LOC14 in MTEC cells. F. Percentage of IAV NP+ primary mouse tracheal epithelial cells
24 h post infection with IAV or mock virus following treatment with LOC14 or vehicle control. G. EC50 of LOC14 determined from percentage of infected cells from F.
H. Significant decreases in PDI activity in the cells treated with LOC14. * * p < 0.01 by t-test.
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oligomerization of HA using non-reducing SDS-PAGE. Mature HA tri-
mers are known to be resistant to dissociation by SDS [30,31]. LOC14
treatment increased monomeric HA and correspondingly decreased
high molecular weight HA (150–200 kDa) as compared to vehicle
treated controls (Fig. 3E, right lanes, -DTT). Samples reduced using DTT
showed no high molecular weight HA (Fig. 3E, left lanes, +DTT). In-
dicating LOC14 induces defects in HA oligomerization by altering oxi-
dative folding of HA. Interestingly, we observed a small decrease in
monomeric forms of HA0 and a marked decrease of HA1 in LOC14
treated samples compared to vehicle control samples infected with IAV
(Fig. 3E, left lanes, +DTT). Potentially suggesting a decrease in overall
HA production following LOC14 treatment.
Our analysis of IAV burden in these cells showed a decrease in IAV-
PA transcripts following LOC14 treatment, but this was not statistically
significant (Fig. 3F). However we observed a significant decrease in the
number of MTECs positive for IAV NP in LOC14 treated IAV infected
cells as compared to vehicle control treated cells (Fig. 3G & S2B). Next,
reinfection of MTECs with supernatants isolated from earlier infected
MTECs treated with either vehicle or LOC14 showed a marked decrease
in the number of cells positive for IAV NP in LOC14 treated super-
natants as compared to vehicle treated supernatants (Fig. 3H & S2C),
suggesting a decreased production of infectious virus following LOC14
treatment. Quantification of mRNAs for Ccl20, and Irf7, an important
transcriptional regulator of the type I interferon response by RT-qPCR
showed a significant decrease in transcript levels following LOC14
treatment, suggesting decreased viral burden (Fig. 3I & J).
LOC14 is known to be a potent activator of the unfolded protein
response (UPR)[23]. In order to assess UPR due to LOC14 treatment, we
examined UPR activation, by monitoring ATF6 cleavage and GRP78
protein expression, two transducers of the UPR, and measurement of
active caspase-3. Our results showed no significant increases in either
readout in LOC14 treated samples, indicating LOC14 (30 µM) treatment
had no effect on cellular stress levels of either mock or IAV infected
cells 24 h post infection (Fig S2D & S2E).
Taken together these results suggest that LOC14 alters oxidative
folding of HA, and that deficit in the formation of disulfide bonds has
significant implications for oligomerization of HA and subsequent in-
fluenza burden in MTECs.
2.4. LOC14 treatment alters oxidative folding of different HA in H3N2
serotype
Owing to remarkable conservation of cysteine residues between
various strains of influenza (Fig S3) we sought to determine if altera-
tions in oxidative folding also affected other hemagglutinin serotypes
e.g. H3. To determine the effects of LOC14 treatment on H3 HA, we
infected MTECs with X31 which contains the HA and NA genes of A/
Aichi/1/1968 (H3N2) [32]. Primary MTECs were treated with LOC14
Fig. 3. LOC14 treatment in primary mouse tracheal epithelial cells (MTECs) decreases -S-S- of HA and viral burden. A. Schematic representing the time points
of IAV infection and LOC14 treatment. B. Western blot analysis of PR8 HA0/HA1 of cells treated as in A. GRP94 was used as a loading control. Duplicates (mock) and
triplicates (IAV) of identical conditions are shown. C. Schematic depicting biotin switch assay and subsequent labeling of reduced sulfhydryl groups by MPB. D.
Western blot analysis of thiol content of IAV HA following LOC14 treatment by MPB labeling and neutravidin pulldown. E. Western blot analysis of HA oligo-
merization following LOC14 treatment of IAV infected cells, samples analyzed by reducing (+DTT) and non-reducing (-DTT) run on a SDS-PAGE. F. mRNA ex-
pression of IAV PA from cell lysates of mock infected and IAV infected primary MTECs analyzed by RT-qPCR. G. Percentage of IAV NP+MTECs following LOC14
treatment, *p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-VC group by ANOVA. H. Percentage of IAV NP+MTECs following exposure to LOC14
or vehicle control treated supernatant from F, *p < 0.05 compared to VC group by t-test. I and J. mRNA expression of Irf7 and Ccl20 from cell lysates of mock
infected and IAV infected primary MTECs analyzed by RT-qPCR. PCR results were normalized to housekeeping gene Gapdh. *p < 0.05 compared to mock groups,
#p < 0.05 compared to IAV-VC group by ANOVA. Data are expressed as means (± SEM) of 3 samples per group.
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pre- and post-infection with X31 (Fig. 3A). LOC14 treatment did not
alter HA0 levels compared to vehicle treated cells (Fig. 4A, WCL-WB).
However, levels of cleaved HA1 showed a significant decrease following
LOC14 treatment (Fig. 4A, WCL-WB, top panel, Fig S4A). The biotin
switch assay followed by neutravidin pull-down showed considerably
less disulfide bonds in IAV-HA (H3) following LOC14 treatment
(Fig. 4A, neutravidin-WB, bottom panel). We then examined oligo-
merization of HA using non-reducing SDS-PAGE. LOC14 treatment
decreased high molecular weight HA (150–200 kDa) as compared to
vehicle treated controls (Fig. 4B, right lanes, -DTT), while samples re-
duced using DTT showed no high molecular weight HA (Fig. 4B, left
lanes, +DTT), though no corresponding increase in monomeric HA was
observed. These results suggest that a decrease in oxidative folding in
the form of -S-S- bonds of HA leads to impaired oligomerization in H3-
HA of X31. Again, we observed a decrease in monomeric forms of HA0
in LOC14 treated samples compared to vehicle control samples infected
with IAV (Fig. 4B, left lanes, +DTT). Potentially suggesting that a de-
crease in overall HA production following LOC14 treatment.
Subsequent analysis of IAV burden in these cells showed a sig-
nificant decrease in IAV-PA transcripts following LOC14 treatment
(Fig. 4C), and a significant decrease in the number of MTECs positive
for IAV-NP in LOC14 treated IAV infected cells as compared to IAV
infected vehicle control treated cells (Fig. 4D, S4B). Next, reinfection of
MTECs with supernatants isolated from earlier infected MTECs treated
with either vehicle or LOC14 showed a marked decrease in the number
of cells positive for IAV NP, suggesting decreased production of
infectious virus following LOC14 treatment (Fig. 4E, S4C). Quantifica-
tion of Ccl20, and Irf7, by RT-qPCR showed a significant decrease in
transcript levels following LOC14 treatment (Fig. 4F and G). Taken
together these results suggest that LOC14 decreases -S-S- bonds of H1 as
well as H3 HA, and that these variations in disulfide bonds have sig-
nificant implications for oligomerization of HA and subsequent in-
flammatory response independent of influenza strain.
2.5. Ablation of Pdia3 in the lung epithelium attenuates viral burden in mice
To determine whether PDIA3 in airway epithelial cells contributes
to the establishment of viral burden, lung inflammation and airway
mechanics, we generated a doxycycline inducible transgenic CCSP-
rTetA/TetOP-Cre/Pdia3loxp/loxp (ΔEpi-Pdia3) mouse to delete Pdia3 spe-
cifically in lung epithelial cells. Mice carrying TetOP-Cre/Pdia3loxp/loxp
or CCSP-rTetA/TetOP-Cre were used as littermate controls (Ctr).
Characterizations of these mice are described elsewhere [6]. All mice
were kept on doxycycline for the length of the experiment beginning
seven days prior to IAV infection to ensure ablation of Pdia3 throughout
the infection protocol (Fig. 5A). Our previous work with these trans-
genic mice show clear decrease of PDIA3 following doxycycline ex-
posure in the lung epithelial cells [6]. RT-qPCR analysis of viral tran-
scripts (IAV-PA, -HA, and –NA) in lung extracts showed significantly
decreased viral load as evidenced from the influenza markers that are
examined in ΔEpi-Pdia3 mice compared to Ctr mice (Fig. 5B-D). Strik-
ingly, Western blots showed that HA protein levels were significantly
Fig. 4. LOC14 treatment alters oxidative folding of different HA in H3N2 serotype. A. Western blot analysis of X31 HA0/HA1, GAPDH was used as a loading
control (top panel), Western blot analysis of thiol content of IAV HA following LOC14 treatment by MPB labeling and neutravidin pulldown (bottom panel). B.
Western blot analysis of HA oligomerization following LOC14 treatment of IAV infected cells, samples analyzed by reducing (+DTT) and non-reducing (-DTT) run on
a SDS-PAGE. C. mRNA expression of IAV PA from cell lysates of mock infected and IAV infected primary MTECs analyzed by RT-qPCR, *p < 0.05 compared to mock
groups, #p < 0.05 compared to IAV-VC group by ANOVA. D. Percentage of IAV NP+MTECs following LOC14 treatment by flow cytometry, *p < 0.05 compared
to mock groups, #p < 0.05 compared to IAV-VC group by ANOVA. E. Percentage of IAV NP+MTECs following exposure to LOC14 or vehicle control treated
supernatant from E by flow cytometry, *p < 0.05 compared to VC group by t-test. F and G. mRNA expression of Irf7 and Ccl20 from cell lysates of mock infected and
IAV infected primary MTECs analyzed by RT-qPCR. PCR results were normalized to housekeeping gene Gapdh. *p < 0.05 compared to mock groups, #p < 0.05
compared to IAV-VC group by ANOVA. Data are expressed as means (± SEM) of 3 samples per group.
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Fig. 5. Ablation of Pdia3 in the lung epithelium attenuates viral burden and inflammation in mice. A. Schematic representing the time points of IAV infection
and doxycycline treatment and euthanasia of mice. B-D. Analysis of mRNA for influenza proteins (PA, HA and NA) in whole lung lysate by RT-qPCR, results
normalized to the geometric mean of housekeeping genes Pp1b and Gapdh, *p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-Ctr group by ANOVA.
E. Western blot analysis of IAV HA in Ctr and ΔEpi-Pdia3 mice, GRP94 was used as a loading control. * Indicates nonspecific band. F. Western blot analysis of HA
oligomerization following ablation of PDIA3 in the airway epithelium, samples analyzed by reducing (+DTT) and non-reducing (-DTT) SDS-PAGE. G and H. ELISA
for CXCL1 and CCL20 from whole lung homogenates, *p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-Ctr group by ANOVA. I-L. Analysis of
inflammatory and immune cells in the BALF by hema 3 stain and differential counting, *p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-Ctr group
by ANOVA. Data are expressed as means (± SEM) of 6–10 mice/group.
Fig. 6. Ablation of Pdia3 in the lung epithelium attenuates influenza-mediated methacholine induced AHR. A-C. Assessment of AHR via a forced oscillation
technique in Ctr and ΔEpi-Pdia3 mice. Saline was administered to determine baseline Newtonian resistance (Rn), tissue resistance (G), and tissue elastance (H),
*p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-ΔEpi-Pdia3 group by ANOVA. D-F. Methacholine (12.5–50mg/mL) induced AHR represented as
percent increase from saline following exposure to increasing doses of methacholine. *p < 0.05 compared to mock groups, #p < 0.05 compared to IAV-ΔEpi-Pdia3
group by ANOVA. Data are expressed as means ( ± SEM) of 6–10 mice/group.
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decreased following lung epithelial Pdia3 ablation (Fig. 5E, Fig S5).
Accordingly, these decreases in HA also resulted in decreased HA oli-
gomers (150–200 kDa) in- ΔEpi-Pdia3 mice compared to Ctr mice
(Fig. 5F). Taken together these results suggest lung epithelial PDIA3
plays an important role in efficient HA production and IAV burden in
vivo.
We next determined if this decrease in viral burden due to Pdia3
deletion led to a concomitant decrease in influenza-induced in-
flammation. Analysis of chemokines in the lung tissues showed that
production of neutrophil chemoattractant CXCL1 and dendritic/mac-
rophage chemoattractant CCL20 were decreased in IAV-infected ΔEpi-
Pdia3mice when compared with IAV-infected Ctrmice. (Fig. 5G and H).
Analysis of total cells in bronchoalveolar lavage fluid (BALF) also
showed a significant decrease in inflammatory cell numbers in ΔEpi-
Pdia3mice infected with IAV as compared to Ctrmice infected with IAV
(Fig. 5I). Quantitation of specific inflammatory cell types revealed
significant attenuation of total macrophages, neutrophils, and lym-
phocytes in IAV infected ΔEpi-Pdia3 mice when compared with IAV
infected Ctr mice (Fig. 5J-L).
2.6. Ablation of Pdia3 in the lung epithelium attenuates influenza-induced
airway hyperresponsiveness (AHR)
Viral infection is known to increase methacholine sensitivity and
AHR in mice and humans [33–35]. Therefore, we examined the con-
sequence of epithelial specific deletion of Pdia3 on AHR to increasing
doses of inhaled methacholine. Following the saline (vehicle control for
methacholine) challenge, peripheral airway resistance (G), but not
central airway resistance (Rn) or parenchymal tissue elasticity (H), was
elevated in control (Ctr) mice infected with IAV compared to mock
infected Ctr mice, suggesting that IAV caused dysfunction of the small
airways and/or lung parenchyma [36] (Fig. 6A-C). However, there was
no increase in G in ΔEpi-Pdia3 mice infected with IAV. Furthermore,
methacholine challenges showed that IAV increased AHR as measured
by changes in both Rn and G; however the severity of the AHR mea-
sured by both G and Rn was significantly decreased in IAV-infected
ΔEpi-Pdia3 mice (Fig. 6D & E). This suggests that due to IAV infection,
the presence of PDIA3 increases responsiveness to methacholine and
results in constriction of the central and peripheral airways. Taken to-
gether these results suggest that lung epithelial PDIA3 plays an im-
portant role in the establishment of IAV burden, inflammation, and
AHR
3. Discussion
The pathogenesis of IAV involves a complex interplay between
numerous host and viral factors [37]. Additional understanding of the
influenza virus as well as the host cellular pathways utilized by IAV
would provide valuable insight toward the development of novel
therapeutic and preventative modalities less dependent on viral anti-
genic shift and drift.
Recent studies have suggested that several PDIs play important roles
in influenza pathogenesis [17,38]. However only the calnexin/calreti-
culin associated, glycoprotein specific PDIA3 is known to be directly
involved in the processing of IAV hemagglutinin (HA), one of the major
antigenic determinants of the virus [15,17,39]. Disrupting this PDIA3-
HA interaction provides an intriguing therapeutic target. While there is
a large amount of diversity in IAV hemagglutinin [40], the cysteine
residues involved in disulfide bonding are highly conserved (Fig S3),
highlighting their importance in the structure and function of HA.
Herein, we show that PDIA3 levels are increased following IAV in-
fection, and PDIA3 transcript levels are upregulated compared with
other PDIs. Treatment with a reversible PDI inhibitor LOC14 results in
altered -S-S- bonds in both H1 and H3 HA along with associated al-
terations of HA maturation and subsequent decreases in markers of
viral infection, demonstrating potent anti-influenza activity
independent of viral strain. While LOC14 is known to be a potent UPR
activator [23], 24 h post LOC14 treatment the cells do not show signs of
exacerbated cellular stress or enhanced apoptosis. Furthermore, genetic
ablation of Pdia3 in the airway epithelium, the primary site of influenza
infection, results in a similar phenotype of diminished overall viral
load. Finally we also show restoration of normal lung mechanics fol-
lowing Pdia3 ablation in IAV infected mice. Taken together our results
suggest the importance of lung epithelial PDIA3 in formation of -S-S-
bonds of IAV HA and subsequent establishment of IAV infection, airway
inflammation and AHR.
PDIs play critical roles in oxidative folding of proteins, catalyzing
and isomerizing disulfide bonds [7]. PDIA3 is required for the efficient
folding of HA by catalyzing and isomerizing disulfide bonds and en-
suring proper cysteine pairings [15]. Past work has demonstrated the
necessity of these disulfides in the proper folding of HA, as well as in the
formation of the HA trimer and its transport through the secretory
system of the cell to the plasma membrane [14,41], potentially linking
oxidative folding to viral assembly. LOC14 treatment led to significant
alterations of the disulfide bonds of both H1 and H3 HA. Regardless of
IAV strain, HA cleavage occurs after it has left the ER, either in the
Golgi or at the cell surface [42,43]. Following LOC14 treatment we
observe a marked decrease in HA1, which suggests that altered oxida-
tive folding prevents the normal proteolytic processing of HA. Studies
involving HA mutants lacking the ability to form proper disulfide bonds
demonstrate retention of the mutant misfolded HA in the ER and en-
hanced proteasome-mediated degradation [14,44–47].
HA is known to oligomerize to its SDS resistant trimeric con-
formation within the ER regardless of ATP concentration, blocked
transport from the ER, temperature alterations, and the trimming of
carbohydrate side chains [31]. This suggests that trimerization is lar-
gely dependent on the acquisition of the proper tertiary structure of the
HA0 monomers. Impairment of proper disulfide bond formation has
been shown to hinder detection of correctly folded trimeric HA;
moreover, Pdia3 deletion has shown to cause a decreased number of HA
molecules acquiring its trimeric structure [14,15]. We found that PDI
inhibition with LOC14 resulted in a similar phenotype, causing a
marked decrease in the appearance of high molecular weight SDS re-
sistant HA species combined with concomitant increases in monomeric
H1-HA, though no increase in monomeric H3-HA was observed. Col-
lectively, these results suggest that alteration in HA maturation (oli-
gomerization) is driven by intramolecular -S-S- bonds rather than other
protein modifications.
Interestingly we observe variable decreases in HA0 levels following
LOC14 treatment for both H1-HA and H3-HA on Western blots. These
variations may be due to differences in the amount of protein used as
well as different gel-running time for the various Western blots.
While LOC14 treatment has an effect on the folding of HA, at this
juncture, it is not possible to determine which PDIs are being affected.
LOC14 has been extensively characterized against PDIA1, the proto-
typical member of the PDI family. It has been proposed in the literature
that LOC14 would be effective against other PDI family members owing
to high sequence homology and conservation of the active site, though
this has yet to be verified [18,22]. siRNA experiments have shown
PDIA1, 3, and 4 all play some role in influenza infection, leading to
significant decreases in viral replication, though no viral proteins that
reach the plasma membrane through the secretory pathway were ex-
amined [38]. Thus the effects we see could be the result of LOC14 in-
hibiting multiple PDIs, though PDIA3 is the only PDI directly involved
in HA maturation [15]. However a lack of specificity would theoreti-
cally result in substantial loss of PDI activity in cell lysates treated with
LOC14; while we observe significant decreases in PDI activity there is
nonetheless high background signal in lysates of cells treated with
LOC14. This could suggest that DiE-GSSG might be able to act as a
substrate for other redox active cellular proteins such as thioredoxins or
glutaredoxins. Another possibility is an alteration of the equilibrium
between the bound and unbound inhibitor, the inhibitory capacity of
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LOC14 may be altered under diluted assay conditions. Further refine-
ment and experimentation are needed to accurately assess the biolo-
gical capacity of LOC14 on PDI activity in influenza-infected cells.
LOC14's lack of specificity toward a single PDI may also explain
differences in chemokine levels following treatment. Various PDIs
might be involved more directly in not only the production, but also the
secretion of these chemokines or other cytokines, for example, PDIA1 is
found at high levels in the secretory granules of eosinophils [48], and
we have previously shown siRNA knockdown or ablation of Pdia3 in
lung epithelial cells decreases various cytokine levels, and alters oxi-
dative folding of Eotaxin, EGF and Periostin in mice [6].
The lack of specificity of LOC14 also leaves open the possibility of
inhibiting not only PDIs but also other oxidoreductaes with thiredoxin
fold [18,49]. Thioredoxin reductases utilize selenocysteine to mediate
their effects [50], as such the potential interactions with LOC14 are
harder to predict. Direct interaction between these proteins and viral
HA is unlikely, as they are not found in high abundance within the
ER [49,50]. Previous work has demonstrated treatment with glu-
tathione derivatives significantly decreases influenza replication, which
was attributed to an alteration in the redox state of PDIs [51], sug-
gesting the importance of the redox buffering capacity of the cell for
influenza replication. We predict that if LOC14 is able to interact with
these redox-buffering enzymes it would allow for the possibility of
additional indirect inhibition of PDIs, though extensive experimenta-
tion would be required to accurately determine additional LOC14 tar-
gets.
To investigate the role of PDIA3 during IAV infection in vivo we
deleted Pdia3 specifically in the lung epithelium. Our results show de-
letion of Pdia3 in the lung epithelium significantly decreased overall
viral load. Moreover we show Pdia3 deletion significantly attenuates
IAV mediated airway inflammation and AHR. Pdia3 deletion strikingly
ablates increases in peripheral airway resistance found in control mice
following IAV infection. Viral infection is known to induce or exacer-
bate AHR in humans and mice [33,34], and present data provides
strong evidence that deletion of PDIA3 in the lung epithelium leads to
relevant improvements of lung mechanics. The protection against
changes in Rn and G during methacholine challenge suggest the
changes are due to reduced airway narrowing of both large and small
airways [52,53]. While the lack of effect on H suggests that is does not
change the severity of airway closure during methacholine challenge
[54]. Though it remains possible the reduction in AHR is simply due to
decrease in viral burden following ablation of Pdia3.
Interestingly HA levels were severely decreased after ablation of
PDIA3, pointing to a potential role for PDIA3 in influenza entry into the
cell. In certain cells PDIA3 found on the plasma membrane is known to
play an important role in gamete fusion, act as a receptor for certain
vitamins, and facilitate HIV entry [55–57]. However experiments using
cell impermeable PDI inhibitors showed little impact on influenza re-
plication, suggesting PDIA3's role in influenza propagation may be
limited to protein maturation in the ER [38].
In conclusion, our findings support that PDIA3 activity is involved
in IAV replication, specifically in the oxidative folding of IAV HA.
Interestingly this effect appears to occur independent of influenza
strain. Lung epithelial specific ablation of Pdia3 suggested that IAV
infection and spread may require Pdia3 in vivo and ablation of Pdia3
also decreased inflammatory markers as well as virus load in the lung.
These results suggest that inhibiting PDIA3 during influenza infection
may decrease viral load and improve lung mechanics. Furthermore, we
have shown that a reversible, small molecule PDI inhibitor LOC14 has
anti-influenza activity and may form a potential basis for future anti
influenza therapeutics by inhibiting PDIs.
4. Material and methods
4.1. Ethics statement
All animal studies were approved by the University of Vermont
Institutional Animal Care and Use Committee and carried out in ac-
cordance with the Guide for the Care and Use of Animals of the
National Institutes of Health. The University of Vermont adheres to the
“U.S. Government Principles for the Utilization and Care of Vertebrate
Animals Used in Testing, Research, and Training”, “PHS Policy on
Humane Care and Use of Laboratory Animals”, “USDA: Animal Welfare
Act & Regulations”, and “the Guide for the Care and Use of Laboratory
Animals”. The University is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care International
(AAALAC). University of Vermont's PHS Assurance Number: A3301-01,
expiration date: October 31, 2021. University of Vermont IACUC was
approved on July 30, 2013, and the animal protocol number is 13–063.
The de novo renewal was approved on July 17, 2018, and the animal
protocol number is 13–063.
4.2. Viruses
Influenza A virus Puerto Rico 8/34 (H1N1) (10100374) and A X-31,
A/Aichi/68 (H3N2) (10100375) were purchased from Charles River.
4.3. Cells and treatments
Primary MTECs were isolated and cultured from age and sex mat-
ched wild type (WT) C57BL/6NJ mice as previously described [6]. Cells
were plated at 2×106 cells/dish and when greater than 90% confluent,
infected with mouse-adapted H1N1 influenza A virus Puerto Rico 8/34
(PR8) or H3N2 A X-31, A/Aichi/68 (X31) at 2.5 Egg infectious units
(EIU)/cell in a DMEM/F12 (Gibco) growth factor–free medium. Ultra-
violet light (UV)–irradiated virus that was replication-deficient (mock)
was used as a control. Following infection the cells were incubated for
1 h at 37 °C, the plates were then washed twice with 2mL PBS to re-
move unbound virus, and supplemented with growth factor–free
medium. MTECs were pretreated for 2 h with 10 μM LOC14 (Tocris,
5606), during viral infection, and 1 h post viral infection, DMSO was
used as a control. All treatments were performed in growth factor–free
medium.
4.4. Transgenic mice
Bitransgenic mice carrying the rat club cell secretory protein (CCSP)
promoter 5′ to the open reading frame for the reverse tetracycline
transactivator (CCSP-rtTA; line 1, which in adult lungs is expressed in
bronchiolar and type II epithelial cells) [58] plus 7 tetracycline operon
5′ to the open reading frame for Cre recombinase (TetOP-Cre) mice
were provided by Dr. Whitsett (Cincinnati Children's Hospital) [59].
CCSP-rtTA+, TetOP-Cre+ mice were bred with mice carrying the
Pdia3loxp/loxp alleles [60]. Mice expressing CCSP-rtTA/TetOP-Cre/
Pdia3loxp/loxp were used to ablate Pdia3 from lung epithelial cells (de-
noted as ΔEpi-Pdia3) by feeding doxycycline-containing chow (6 g/kg;
Purina Diet Tech, St Louis, Mo) 7 days before exposure to virus. Mice
were maintained on doxycycline-containing food until completion of
the experiment. Double-transgenic littermates containing either CCSP-
rtTA/TetOP-Cre or CCSP-rtTA/Pdia3loxp/loxp (Ctr mice) and fed doxycy-
cline-containing food were used as controls in the experiments.
4.5. Assessment of AHR
Mice were anesthetized by IP injection of pentobarbital solution
(90mg/kg), tracheotomized with an 18 gauge cannula, then mechani-
cally ventilated at a rate of 200 breaths/min using a FlexiVent computer
controlled small animal ventilator (SCIREQ). While on ventilators mice
N. Chamberlain et al. Redox Biology 22 (2019) 101129
9
received the paralytic, pancuronium bromide. Parameters of Newtonian
resistance (Rn), tissue dampening (G), and elastance (H) were calcu-
lated as previously described [61]. Airway hyperresponsiveness is re-
presented as the average of the three peak measurements for each an-
imal, obtained at increasing methacholine doses.
4.6. Bronchoalveolar lavage processing
Bronchoalveolar lavage fluid (BALF) was collected by lavaging
lungs with 1.0mL of sterile PBS. Cells were isolated by centrifugation,
and total cell counts were determined using a hemocytometer (Hausser
Scientific) on an Inverted Infinity and Phase Contrast Microscope
(Fisher Scientific). Differential cell counts were obtained via cytospins
using Hema3 stained (Fisher Scientific) total cells. Differentials were
performed on a minimum of 300 cells/animal.
4.7. Analysis of mRNA expression
Right lung lobes were flash-frozen and pulverized, and total RNA
was isolated using Qiazol Lysis Reagent (Qiagen) and purified using the
RNeasy kit (Qiagen). One microgram of RNA was reverse transcribed to
cDNA for quantitative assessment of gene expression using SYBR green
(Bio-Rad). Expression values were normalized to indicated house-
keeping gene(s). The primers used in this study are listed in
Supplemental Table 1.
4.8. Western blot analysis
Following dissection, right lung lobes were flash-frozen for protein
or mRNA analysis. Lungs were pulverized and lysed in buffer containing
20mM Tris·HCl (pH 8.0), 100mM NaCl, 0.5% Nonidet P-40, 10% gly-
cerol, and 1% protease inhibitor cocktail (Sigma-Aldrich, P8340) (v/v),
1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726,
P0044) (v/v). Proteins from cell lysates were prepared in the same
buffer. Insoluble proteins were pelleted via centrifugation. Following
protein quantitation of the supernatant, samples were resuspended in
loading buffer with dithiothrietol and resolved by SDS-PAGE. Proteins
were transferred to PVDF, and membranes were probed using a stan-
dard immunoblotting protocol. Protein quantification of supernatant
was determined using DC Protein Assay (Bio-Rad, 5000116). Samples
were resuspended in loading buffer with dithiothrietol and resolved by
SDS-PAGE. The quantification of protein expression was performed by
densitometry using Image Studio Lite software (LI-COR Biosciences).
Antibodies used for western blots can be found Supplemental Table 2
4.9. Image processing
Digital images were acquired using an Amersham Imager 600RGB
(GE). Photoshop (CC 2018; Adobe) and Illustrator (CC 2018; Adobe)
were used to assemble the figures. Samples were run on the same gel.
When required, brightness and contrast were adjusted equally in all
lanes.
4.10. ELISA
Lung protein samples were assayed for CXCL1 (DY453, R&D) and
CCL20 (DY760, R&D) by ELISA according to the manufacturer's in-
structions.
4.11. Non-reducing gel electrophoresis
Lung homogenates were resuspended in loading buffer without the
reducing agent dithiothrietol (DTT). A separate set of samples were
resuspended in loading buffer with DTT and incubated at 95 °C for
10min to reduce the disulfide bonds. The samples were resolved by
SDS-PAGE and subjected to western blot analysis as described.
4.12. Immunofluorescence
Following euthanization, left lobes were fixed with 4% paraf-
ormaldehyde, stored at 4 °C overnight for fixation of the tissue,
mounted in paraffin, and 5 µm sections were affixed to glass microscope
slides for histopathology as previously described [61]. Sections were
prepared for immunofluorescence by deparaffinizing with xylene and
rehydrating through a series of ethanols. For antigen retrieval, slides
were heated for 20min in 95 °C pH 6.0 sodium citrate buffer with
0.05% TWEEN-20 then rinsed in dH2O. Sections were then blocked for
1 h in 1% BSA in PBS, followed by incubation with primary antibody for
PDIA3 (LSBio, LS-B9768) at 1:300, overnight at 4 °C. Slides were then
washed 3×5min in PBS, incubated with Alexafluor 647 at 1:1000 in
1% BSA, and counterstained with DAPI in PBS at 1:4000 for nuclear
localization. Sections were imaged using a Zeiss 510-META confocal
laser-scanning microscope. Images were captured at x40 magnification
in oil immersion. The image files were converted to Tiff format.
Brightness and contrast were adjusted equally in all images.
4.13. PDIA3 activity assay
PDI disulfide reduction activity was monitored in PDI assay buffer
containing 0.1M potassium phosphate buffer pH 7.0 and 2mM EDTA
by adding 10 ng recombinant human PDIA3 (Prospec, ENZ-474) or 2 μg
MTEC lysate to 150mM DiE-GSSG (Cayman, 11547) in the presence of
5 μM DTT. DiE-GSSG is comprised of two eosin molecules attached to
oxidized glutathione, resulting in proximity quenching of the eosin
molecules. Upon reduction of the -S-S- bond (i.e. PDIs, DTT), fluores-
cence emission of eosin increases dramatically [25]. The increase in
fluorescence signal was monitored at 528 nm with excitation at 485 nm
using a Synergy HTX plate reader (Biotek). The total reaction volume
was 100 μL. For inhibition of PDIA3 the reaction mixture was incubated
with LOC14 (Tocris, 5606) at the indicated concentrations for 30min
on ice prior to the addition of DiE-GSSG. IC50s were calculated using
GraphPad Prism (version 7.0, GraphPad); briefly initial rates of fluor-
escence over time were determined over the first 10min for indicated
inhibitor concentrations, IC50s were then determined using three-
parameter non-linear regression.
4.14. Biotin switch assay
To block free sulfhydryls, cells were lysed in buffer containing
20mM Tris·HCl (pH 8.0), 100mM NaCl, 0.5% Nonidet P-40, 10% gly-
cerol, 1% protease inhibitor cocktail (Sigma-Aldrich, P8340) (v/v), 1%
phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726, P0044)
(v/v), and 1mM N-Ethylmaleimide (NEM) for 1 h at ambient tem-
perature. Excess NEM was then removed via acetone precipitation.
Briefly, Acetone was cooled to −20 °C. Four times the sample volume
was added to protein samples. Samples were then vortexed and in-
cubated overnight at −20 °C. Precipitated protein was pelleted by
centrifugation at 14,000×g for 10min. The supernatant was aspirated
and the resulting pellet was suspended in buffer containing 20mM
Tris·HCl (pH 8.0), 100mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1%
SDS, and 1% protease inhibitor cocktail (Sigma-Aldrich, P8340) (v/v),
1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726,
P0044) (v/v). Upon resuspension disulfides were reduced with 20 μM
DTT and newly formed sulfhydryl groups were labeled with 1mM 3-(N-
maleimido-propionyl) biocytin (MPB) (Invitrogen, M1602) for 1 h at
ambient temperature. Excess DTT and MPB were removed via acetone
precipitation. The labeled lysate was precipitated using NeutrAvidin
agarose resin (Thermo Scientific, 29200) and subsequently probed
using an anti-HA antibody. As a reagent control lysates from cells were
incubated with DMSO and subjected to the same procedures.
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4.15. Flow cytometry
The following antibodies were used for flow cytometric staining:
anti-IAV NP (Abcam, ab20921), Mouse IgG1 isotype control (Abcam,
ab91356). Intracellular staining was performed using the BD Cytofix/
Cytoperm kit (Becton Dickinson, 554714), according to the manu-
facturers instructions. All samples were run on a Guava easyCyte HT
cytometer (Millipore) and analyzed using Flowjo (version 10.4.2,
TreeStar)
4.16. Statistics
Data were analyzed by one-way analysis of variance (ANOVA) and a
Tukey's post-hoc test to adjust for multiple comparisons, or student's t-
test where appropriate. Statistical analysis was performed using Graph
Pad Prism (version 7.0, Graph Pad). A p value< 0.05 was considered
significant. Data from multiple experiments were averaged and ex-
pressed as mean values± SEM.
4.17. Microarray analysis
GEO2R (www.ncbi.nlm.nih.gov/geo/info/geo2r.html) was used to
perform comparisons on differentially expressed genes between influ-
enza-infected samples and normal controls on GSE63786 and
GSE48466. GEO2R automatically performs a base 2 log transformation.
4.18. Caspase assay
25 μg of treated MTEC lysate was brought to 25ul with dH2O and
25ul Caspase-Glo 3/7-assay reagent (Promega, G8091) were mixed and
incubated in the dark at ambient temperature for 20min. Total lumi-
nescence was monitored using a Synergy HTX plate reader (Biotek).
Values were expressed as relative luminescence units.
4.18.1. Small interfering (si)RNA treatment
Mouse type II epithelial cells (C10) were cultured as describe pre-
viously [17]. Cells were treated with Accell control small interfering (si)
RNA (Dharmacon, D-001920–02-05) or PDIA3 siRNA (Dharmacon, E-
045187–00) as per manufactures instructions for 24 h prior to infection
with influenza virus or UV-irradiated mock virus.
4.18.2. Immunoprecipitation
HBE cells were lysed in cells were lysed in buffer containing 20mM
Tris·HCl (pH 8.0), 100mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1%
protease inhibitor cocktail (Sigma-Aldrich, P8340) (v/v), 1% phos-
phatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726, P0044) (v/
v). PDIA3 was precipitated using anti-PDIA3 antibody (Enzo Life
Sciences, ADI-SPA-585-F) and Protein G agarose beads (Invitrogen,
15920010). As a control lysates from cells were incubated non-specific
rabbit gamma globulin (Jackson ImmunoResearch, 011–000-002) and
subjected to the same procedures. Samples were run on reducing gels.
Author summary
Current Influenza virus therapies target viral proteins and are lim-
ited in their effectiveness owing to rapid viral mutation. Understanding
host cellular and molecular processes utilized by the virus during its
replication may aid in the development of new therapeutic interven-
tions to improve patient survival. Influenza proteins such as he-
magglutinin (HA) rely on disulfide bonds for stability and activity and
as such rely on host redox enzymes of the endoplasmic reticulum (ER)
and the secretory pathway to express and assemble fully mature viral
proteins. Past work has shown that one of these enzymes, protein dis-
ulfide isomerase (PDI) A3 is important for efficient folding of HA and
viral replication in vitro. However, little is known about how PDIA3
mediates this effect or its role during active viral infection in vivo. Here,
we demonstrate that PDIA3 is required for productive viral infection in
vivo using conditional PDIA3 knockout mice. Moreover, we also show
that small molecule mediated inhibition of PDIs with the reversible
inhibitor LOC14 results in decreased viral replication, inflammation,
and oxidative folding of HA. Thus, PDIA3 and other host redox active
enzymes may provide targets for future therapies, and LOC14 may
provide the basis for novel therapeutic interventions.
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